Tactile Systems Technology (TCMD) Aktienübersicht
Tactile Systems Technology, Inc. ist ein Medizintechnikunternehmen, das medizinische Geräte zur Behandlung unterversorgter chronischer Krankheiten in den Vereinigten Staaten entwickelt und anbietet. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 4/6 |
| Künftiges Wachstum | 3/6 |
| Vergangene Leistung | 4/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 0/6 |
TCMD Community Fair Values
Create NarrativeSee what 23 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Tactile Systems Technology, Inc. Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | US$29.78 |
| 52-Wochen-Hoch | US$37.77 |
| 52-Wochen-Tief | US$11.02 |
| Beta | 0.82 |
| 1 Monat Veränderung | -5.01% |
| 3 Monate Veränderung | 17.71% |
| 1 Jahr Veränderung | 137.48% |
| 3 Jahre Veränderung | 67.12% |
| 5 Jahre Veränderung | -28.88% |
| Veränderung seit IPO | 168.77% |
Aktuelle Nachrichten und Updates
Narrative-Update • Jul 23
TCMD: Margin Expansion And New Therapies Will Support Future Upside
Analysts have lifted their fair value estimate for Tactile Systems Technology to $42.00 from $32.00, citing expectations for stronger profit margins and a slightly higher future P/E multiple, as reflected in recent Street research updates. What’s in the News for Tactile Systems Technology Tactile Systems Technology entered an exclusive distribution agreement with ElastiMed to provide the MyoSleeve non pneumatic lower leg compression device to U.S. Department of Veterans Affairs and Department of Defense patients, with a US$3 million upfront payment, minimum purchase commitments, and planned use of the company’s existing sales and support infrastructure.Seeking Alpha • Jul 14
Tactile Systems: Clean Balance Sheet, But A Possible Value Trap
Summary Tactile Systems Technology is rated Hold, with a 12-month price target of $31, reflecting fair value near 20x P/E. TCMD's strong balance sheet—$83.4M cash, zero debt—and raised guidance are already priced in, limiting upside. Peer history shows cheap, mature MedTech stocks with reimbursement risk tend to underperform, suggesting limited near-term appreciation for TCMD. The key catalyst is the CMS prior-authorization rollout; Q2 results will determine if TCMD can break the value trap pattern. Read the full article on Seeking Alpha
Narrative-Update • Jul 09
TCMD: Index Inclusion And New Respiratory Platform Will Drive Future Upside
Analysts have increased their fair value estimate for Tactile Systems Technology from $16.00 to $36.00, citing updated assumptions around revenue growth, profit margins, and future P/E multiples, which are reflected in recent price target revisions such as the increase highlighted by BTIG. What’s in the News for Tactile Systems Technology Tactile Systems Technology announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation therapy system, with updates focused on patient comfort, ease of use, and connected care capabilities across pediatric and geriatric respiratory patients.Recent updates
Narrative-Update • Jul 23
TCMD: Margin Expansion And New Therapies Will Support Future Upside
Analysts have lifted their fair value estimate for Tactile Systems Technology to $42.00 from $32.00, citing expectations for stronger profit margins and a slightly higher future P/E multiple, as reflected in recent Street research updates. What’s in the News for Tactile Systems Technology Tactile Systems Technology entered an exclusive distribution agreement with ElastiMed to provide the MyoSleeve non pneumatic lower leg compression device to U.S. Department of Veterans Affairs and Department of Defense patients, with a US$3 million upfront payment, minimum purchase commitments, and planned use of the company’s existing sales and support infrastructure.Seeking Alpha • Jul 14
Tactile Systems: Clean Balance Sheet, But A Possible Value Trap
Summary Tactile Systems Technology is rated Hold, with a 12-month price target of $31, reflecting fair value near 20x P/E. TCMD's strong balance sheet—$83.4M cash, zero debt—and raised guidance are already priced in, limiting upside. Peer history shows cheap, mature MedTech stocks with reimbursement risk tend to underperform, suggesting limited near-term appreciation for TCMD. The key catalyst is the CMS prior-authorization rollout; Q2 results will determine if TCMD can break the value trap pattern. Read the full article on Seeking AlphaNarrative-Update • Jul 09
TCMD: Index Inclusion And New Respiratory Platform Will Drive Future Upside
Analysts have increased their fair value estimate for Tactile Systems Technology from $16.00 to $36.00, citing updated assumptions around revenue growth, profit margins, and future P/E multiples, which are reflected in recent price target revisions such as the increase highlighted by BTIG. What’s in the News for Tactile Systems Technology Tactile Systems Technology announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation therapy system, with updates focused on patient comfort, ease of use, and connected care capabilities across pediatric and geriatric respiratory patients.
Narrative-Update • Jun 25
TCMD: Connected Care Rollout And Buybacks Will Support Future Upside
Analysts have raised their price target on Tactile Systems Technology by $2, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E, which together support a slightly higher valuation framework. What's in the News Tactile Systems Technology announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation therapy system, aimed at chronic neuromuscular and respiratory conditions across pediatric and geriatric patients, with updates focused on comfort, ease of use, and connected care features.Narrative-Update • Jun 07
TCMD: Connected Care Launch And Governance Changes Will Support Continued Upside
Analysts have nudged their price target on Tactile Systems Technology to $39.50 from $38, reflecting updated views on fair value, discount rate, revenue growth, profit margin assumptions, and expected future P/E, as highlighted in recent Street research. What's in the News Tactile Systems Technology announced the full commercial launch of its next generation AffloVest high frequency chest wall oscillation therapy system, designed to support long term adherence for chronic neuromuscular and respiratory conditions across pediatric and geriatric patients.Narrative-Update • Apr 23
TCMD: Lymphedema Execution And Multi Year Guidance Will Support Continued Upside
Analysts have lifted the consolidated price target for Tactile Systems Technology to around $38, supported by higher projections for revenue growth, improved profit margins, and a lower assumed future P/E multiple following recent Q4 upside and updated multi year guidance. Analyst Commentary Recent Street research on Tactile Systems Technology highlights a range of views on execution, growth prospects, and valuation following the Q4 results and updated multi year guidance.Analyseartikel • Apr 18
Should You Think About Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD) Now?
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), might not be a large cap stock, but it received a lot of attention...Narrative-Update • Apr 08
TCMD: Lymphedema Momentum And Q4 Execution Will Drive Multi Year Upside
The updated analyst price target for Tactile Systems Technology has been set at $38. This reflects analysts' reactions to recent Q4 outperformance, higher long-term estimates, and ongoing attention to productivity, patient referrals, and the lymphedema business.Narrative-Update • Mar 25
TCMD: Lymphedema Momentum And Q4 Execution Will Support Multi Year Upside
Analysts have lifted the consolidated price target for Tactile Systems Technology to $38, reflecting a series of Street target increases into the $32 to $42 range, supported by recent Q4 outperformance, updated multi year guidance, and progress in productivity and cost controls. Analyst Commentary Street commentary around Tactile Systems Technology is mixed, with several bullish analysts lifting targets on the back of Q4 execution and longer term guidance, while more cautious voices question how much upside remains after the post earnings re rating.Narrative-Update • Mar 09
TCMD: Lymphedema Momentum And Q4 Execution Will Support Ongoing Upside Potential
Analysts have nudged their average price target for Tactile Systems Technology to $38. This reflects stronger recent Q4 execution, raised long term estimates and ongoing improvements in productivity, patient referrals and cost controls.Narrative-Update • Feb 23
TCMD: Lymphedema Momentum And Q4 Execution Will Support Measured Turnaround Expectations
The analyst fair value estimate for Tactile Systems Technology has been raised from $29.75 to $38.00, reflecting higher Street price targets in the $32 to $42 range as analysts cite recent Q4 upside, improved productivity and cost controls, and ongoing strength in the lymphedema business. Analyst Commentary Street research on Tactile Systems Technology is generally constructive, with higher fair value assumptions linked to recent Q4 performance, execution on productivity and cost controls, and expectations around the lymphedema business.Narrative-Update • Feb 08
TCMD: Index Inclusion And Stable Outlook Will Shape Measured Turnaround Expectations
Analysts have maintained their fair value estimate for Tactile Systems Technology at $29.75 per share. They cited only very small adjustments to assumptions regarding the discount rate, revenue growth, profit margins, and future P/E multiples, rather than any change in the core outlook.Narrative-Update • Jan 25
TCMD: Turnaround Momentum And Buyback Will Test Q3 Outperformance Sustainability
Analysts have raised their price targets on Tactile Systems Technology to a roughly mid to high $20s to low $30s range, citing stronger than expected Q3 results, improved productivity, sales force expansion, new products, and better reimbursement trends that together support a higher fair value assessment. Analyst Commentary Recent research points to a more constructive view on Tactile Systems Technology following its Q3 outperformance, with several firms raising price targets and upgrading ratings based on execution and perceived upside to fair value.Narrative-Update • Jan 10
TCMD: Q3 Turnaround Momentum And Buyback Will Face Execution Risk
Analysts have raised their price target on Tactile Systems Technology to about $29.75 from $24, citing stronger recent earnings performance, expectations for operational improvements, and support for a higher future P/E multiple. Analyst Commentary Recent research updates on Tactile Systems Technology highlight a clear shift toward a more constructive stance, with multiple firms lifting price targets after Q3 results and pointing to both execution progress and valuation support.Analyseartikel • Dec 18
Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 28%
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares have continued their recent momentum with a 28% gain in the...Narrative-Update • Dec 17
TCMD: Q3 Outperformance And Buyback Will Mask Limited Upside Ahead
Analysts have raised their price target on Tactile Systems Technology by about $8.50 to roughly $32 per share, citing significant Q3 outperformance, improving productivity and reimbursement trends, and expectations for a return to double digit growth by 2026. Analyst Commentary Recent research updates reflect a notably more constructive stance on Tactile Systems Technology, with bullish analysts pointing to operational momentum, clearer reimbursement visibility, and a sizable underpenetrated patient pool as key drivers of potential upside in the shares.Narrative-Update • Dec 03
TCMD: Q3 Outperformance And Buyback Plan Will Shape Turnaround Outlook
Analysts have raised their price expectations for Tactile Systems Technology toward the low to mid $30 range, citing a massive Q3 outperformance, consistent estimate beats, and growing confidence in a 2026 growth reacceleration and higher sustainable earnings power. Analyst Commentary Recent Street research reflects a broadly constructive stance on Tactile Systems Technology following its strong Q3 performance and improving fundamentals.Narrative-Update • Nov 19
TCMD: Sustained Product Execution And Buyback Plan Set To Shape Outlook
Analysts have raised their price target on Tactile Systems Technology significantly, from approximately $16.83 to $24.00. They cite strong quarterly outperformance and growing confidence in the company’s turnaround and future growth prospects.Analyseartikel • Nov 06
Results: Tactile Systems Technology, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) investors will be delighted, with the company turning in some strong...Narrative-Update • Nov 03
TCMD: Market Leadership And Coverage Momentum Will Drive Expansion Into Underserved Patients
Narrative Update on Tactile Systems Technology Analysts have reaffirmed their price target for Tactile Systems Technology at $16.83 per share. They cite the company's leadership in key market segments and anticipated growth acceleration as a result of recent strategic improvements.Narrative-Update • Oct 20
At-home Healthcare And Workflow Automation Will Expand Patient Reach
Analysts have maintained their price target for Tactile Systems Technology at $23.50. They cite the company's leading positions in key device markets and an improved outlook following recent strategic adjustments.Narrative-Update • Oct 05
At-home Healthcare And Workflow Automation Will Expand Patient Reach
Analysts have raised their fair value estimate for Tactile Systems Technology from $13.50 to $16.83 per share. The change is attributed to optimism about the company's strengthened market leadership and the potential for renewed growth following recent strategic improvements.Analyseartikel • Oct 04
When Should You Buy Tactile Systems Technology, Inc. (NASDAQ:TCMD)?
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), is not the largest company out there, but it saw a significant share...Analyseartikel • Aug 29
Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Shares Leap 28% Yet They're Still Not Telling The Full Story
Despite an already strong run, Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares have been powering on, with a...Analyseartikel • May 12
Tactile Systems Technology's (NASDAQ:TCMD) Soft Earnings Don't Show The Whole Picture
The most recent earnings report from Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) was disappointing for...Analyseartikel • May 08
Slammed 28% Tactile Systems Technology, Inc. (NASDAQ:TCMD) Screens Well Here But There Might Be A Catch
To the annoyance of some shareholders, Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares are down a considerable...Analyseartikel • May 07
Why Tactile Systems Technology, Inc. (NASDAQ:TCMD) Could Be Worth Watching
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), is not the largest company out there, but it received a lot of...Seeking Alpha • Apr 07
Tactile Systems Technology: Interesting Devices Company, Need More Clarity
Summary Tactile Systems produces medical devices for lymphedema and chronic venous insufficiency, with Flexitouch Plus being the flagship product and key revenue driver. The company's products are covered by major insurers, including Medicare and Veterans Administration, serving over 275 million Americans. Financially, TCMD has a market cap of $311mn, but faces risks from increasing competition, regulatory issues, and ongoing legal matters. Despite strong revenue streams, concerns about falling EBITDA and recent revenue misses warrant a cautious approach before making investment decisions. Read the full article on Seeking AlphaAnalyseartikel • Feb 23
Tactile Systems Technology (NASDAQ:TCMD) Has A Rock Solid Balance Sheet
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analyseartikel • Nov 25
Investors Appear Satisfied With Tactile Systems Technology, Inc.'s (NASDAQ:TCMD) Prospects As Shares Rocket 26%
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) shares have continued their recent momentum with a 26% gain in the...Analyseartikel • Nov 07
Tactile Systems Technology, Inc. Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) came out with its third-quarter results last week, and we wanted to...
Neues Narrative • Sep 24
Nimbl Approval And Tech Investments Propel Growth Amid Shrinking Margins And Operational Risks
Investments in technology and workflow improvements, alongside FDA approval for Nimbl, indicate a strong focus on innovation and market expansion.Analyseartikel • Jul 17
Investors Holding Back On Tactile Systems Technology, Inc. (NASDAQ:TCMD)
With a price-to-sales (or "P/S") ratio of 1.1x Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) may be sending very...Analyseartikel • May 09
US$20.67: That's What Analysts Think Tactile Systems Technology, Inc. (NASDAQ:TCMD) Is Worth After Its Latest Results
Last week, you might have seen that Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) released its quarterly result to...Analyseartikel • Feb 23
Tactile Systems Technology, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Shareholders might have noticed that Tactile Systems Technology, Inc. ( NASDAQ:TCMD ) filed its yearly result this time...Analyseartikel • Oct 10
Does Tactile Systems Technology (NASDAQ:TCMD) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Analyseartikel • Sep 16
Capital Allocation Trends At Tactile Systems Technology (NASDAQ:TCMD) Aren't Ideal
What are the early trends we should look for to identify a stock that could multiply in value over the long term? In a...Analyseartikel • Jul 13
Is It Time To Consider Buying Tactile Systems Technology, Inc. (NASDAQ:TCMD)?
Tactile Systems Technology, Inc. ( NASDAQ:TCMD ), is not the largest company out there, but it saw a significant share...Analyseartikel • May 10
Are Investors Undervaluing Tactile Systems Technology, Inc. (NASDAQ:TCMD) By 26%?
Key Insights Using the 2 Stage Free Cash Flow to Equity, Tactile Systems Technology fair value estimate is US$28.71...Aktionärsrenditen
| TCMD | US Medical Equipment | US Markt | |
|---|---|---|---|
| 7D | 7.4% | 2.3% | 2.4% |
| 1Y | 137.5% | -12.8% | 19.6% |
Rendite im Vergleich zur Industrie: TCMD übertraf die Branche US Medical Equipment , die im vergangenen Jahr eine Rendite von -12.8 erzielte.
Rendite vs. Markt: TCMD übertraf den Markt US, der im vergangenen Jahr eine Rendite von 19.6 erzielte.
Preisvolatilität
| TCMD volatility | |
|---|---|
| TCMD Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 8.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Stabiler Aktienkurs: TCMD hatte in den letzten 3 Monaten im Vergleich zum US -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: TCMDDie wöchentliche Volatilität (6%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1995 | 1,086 | Sheri Dodd | tactilemedical.com |
Tactile Systems Technology, Inc. ist ein Medizintechnikunternehmen, das medizinische Geräte zur Behandlung unterversorgter chronischer Krankheiten in den Vereinigten Staaten entwickelt und anbietet. Es bietet das Flexitouch Plus System, ein pneumatisches Kompressionsgerät zur Behandlung von Lymphödemen, Phlebolymphödemen, Lipödemen, venösen Insuffizienzen und anderen Arten von Ödemen und Beingeschwüren, sowie das Entre Plus System, ein pneumatisches Kompressionsgerät für die Behandlung von Lymphödemen, chronischen Ödemen, venösen Insuffizienzen und chronischen Wunden zu Hause. Das Unternehmen bietet auch Nimbl an, eine pneumatische Kompressionsplattform für die Behandlung von Lymphödemen der oberen Extremitäten; Kylee, eine mobile Anwendung, die Patienten dabei hilft, sich über Lymphödeme zu informieren, ihre Symptome und die Behandlung zu verfolgen sowie ihre Fortschritte mit ihrem Arzt zu teilen; und AffloVest, eine tragbare Hochfrequenz-Brustwand-Oszillationsweste zur Behandlung von Patienten mit zurückgehaltenen Lungensekreten, die durch Bronchiektasie, zystische Fibrose und verschiedene neuromuskuläre Störungen entstehen.
Tactile Systems Technology, Inc.'s Grundlagenzusammenfassung
| TCMD grundlegende Statistiken | |
|---|---|
| Marktanteil | US$671.73m |
| Gewinn(TTM) | US$20.30m |
| Umsatz(TTM) | US$343.52m |
33.1x
Kurs-Gewinn-Verhältnis 2.0x
Kurs-Umsatz-VerhältnisIst TCMD zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| TCMD Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | US$343.52m |
| Kosten der Einnahmen | US$81.11m |
| Bruttogewinn | US$262.41m |
| Sonstige Ausgaben | US$242.12m |
| Gewinn | US$20.30m |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Aug 10, 2026
| Gewinn per Aktie (EPS) | 0.90 |
| Bruttomarge | 76.39% |
| Nettogewinnspanne | 5.91% |
| Schulden/Eigenkapital-Verhältnis | 0% |
Wie hat sich TCMD auf lange Sicht entwickelt?
Historische Performance und VergleicheUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/08/04 18:37 |
| Aktienkurs zum Tagesende | 2026/08/03 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2025/12/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Tactile Systems Technology, Inc. wird von 12 Analysten beobachtet. 5 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| null null | Argus Research Company |
| Kyle Bauser | B. Riley Securities, Inc. |
| Anderson Schock | B. Riley Securities, Inc. |